Result of AGM
RNS & Investor News
First sales of LPLDL® to German market
25 April 2017
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to supply 100,000 units of LPLDL® to HLH BioPharma Vertriebs GmbH ("HLH").
HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and Casa Sana® and is one of Europe's leading suppliers of probiotics to the pharmacy market.
HLH is based in Germany and has established an international reputation for providing high quality and scientifically validated innovative products. LPLDL® will be supplied as bulk capsules which will be packaged and branded as part of HLH's market leading Lactobact® brand.
This pre-launch sale provides moderate levels of early income and reflects the high level of industry awareness in LPLDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. This interest arises from OptiBiotix's innovative science, good clinical data, strong key opinion leader support, and the products ability to reduce both cholesterol and blood pressure. The European Society of Cardiology Studies has reported the ability to reduce both cholesterol and blood pressure 'has a multiplicative effect in reducing cardiovascular risk' providing a significant advantage over single action products.
This sales order is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with a partner's national brand portfolio and market presence to serve multiple consumer healthcare and pharmaceutical markets around the world.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the supply of LPLDL® to HLH which will be sold as part of its market leading Lactobact® brand. We see this as the first step in building sales and market presence of LPLDL® as the 'Intel' inside a wide range of products for cardiovascular health across both consumer and pharmaceutical markets around the world. This creates the opportunity for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner
|Tel: 020 7213 0880|
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020